Counterfeit Cancer Drugs in India: A Racket That Put Desperate Patients at Risk

The arrest of 17 people in connection with an alleged counterfeit and illegally diverted cancer drug network in India has exposed a disturbing threat to patients, hospitals and the wider pharmaceutical supply chain.

Delhi Police say the suspected racket operated across several parts of India, including Delhi, the National Capital Region, Mumbai, Hyderabad, Haryana and Uttar Pradesh. Investigators allege that the network obtained genuine cancer medicines through theft and diversion while also producing counterfeit versions of expensive treatments.

The case is particularly alarming because cancer patients often depend on medicines that can cost tens of thousands or even hundreds of thousands of rupees per vial. For families already struggling with the financial and emotional burden of cancer, a cheaper medicine can appear to offer much-needed relief. According to police, the alleged network exploited exactly that desperation.

How the alleged racket operated

According to police, the medicines entered the network through three main channels.

Some medicines were allegedly diverted from government hospitals and warehouses. Others were reportedly stolen from private hospitals, including vials, medicines and packaging materials. The third route involved the alleged manufacture of counterfeit medicines designed to resemble genuine products.

Investigators said the suspects allegedly reproduced vials and packaging and used fake batch numbers. In some cases, police allege that the counterfeit vials contained sterilised water rather than the active medicines patients needed.

The operation reportedly involved people with experience inside healthcare settings. Police have alleged that some hospital and nursing staff diverted medicines, while others helped move the products through intermediaries.

Raids conducted in Delhi and Navi Mumbai resulted in the seizure of hundreds of filled anti-cancer vials, empty vials, medicine boxes and thousands of other medicines. Police also recovered packaging materials, records and cash. The total value of the medicines and related items was reported at around Rs 90 million, or approximately £688,000.

The case remains an investigation, and the allegations against the accused have not been established in court.

Why counterfeit cancer medicine is especially dangerous

Counterfeit medicines are not simply a financial fraud. They can become a direct threat to life.

Cancer treatments can be highly specialised, and their effectiveness depends on the correct medicine, dose, quality and administration. If a patient receives a product without the required active ingredient, the treatment may fail while the underlying disease continues to progress.

The World Health Organization says falsified medical products can deliberately misrepresent their identity, composition or source. The problem affects both expensive and inexpensive medicines, including oncology treatments. WHO also warns that falsified products can result in treatment failure, adverse reactions and loss of confidence in healthcare systems.

The global nature of the problem is illustrated by recent WHO alerts. In July 2026, WHO issued an alert concerning falsified batches of DARZALEX, a cancer medicine used in the treatment of multiple myeloma and related conditions. The organisation advised patients and healthcare professionals not to use suspected falsified products and stressed the importance of obtaining medicines through authorised suppliers.

This makes the Indian investigation part of a wider international challenge involving the integrity of pharmaceutical supply chains.

The price of desperation

The alleged racket also highlights how financial pressure can create opportunities for criminal networks.

Cancer treatment can place enormous costs on families. When a medicine carries a price of lakhs of rupees, an offer at a substantial discount can be difficult for a desperate family to ignore.

Reports surrounding the investigation say members of the alleged network offered expensive medicines at heavily reduced prices. Investigators reportedly found that some medicines were marketed through informal channels, making it easier to reach people actively searching for cheaper treatment.

This creates a dangerous cycle. The patient believes they have found an affordable alternative, while the seller profits from the urgency surrounding the illness.

The problem is made worse when buyers cannot easily distinguish a genuine medicine from a sophisticated counterfeit. WHO notes that some falsified medical products can look almost identical to genuine products and may therefore be difficult for patients to identify visually.

A challenge for India's pharmaceutical reputation

India plays a major role in the global pharmaceutical industry and is frequently described as the "pharmacy of the world". Its medicines reach patients in countries across the globe, while India itself attracts international patients seeking comparatively affordable healthcare.

That makes confidence in medicine quality particularly important.

Counterfeit drug cases do not mean that medicines manufactured legitimately in India are unsafe. However, high-profile cases involving falsified or diverted medicines can damage public confidence and create additional scrutiny for manufacturers, hospitals, distributors and regulators.

The solution therefore requires more than arrests after a criminal network has already harmed patients. It requires stronger monitoring throughout the medicine supply chain, from manufacturers and distributors to hospitals, pharmacies and patients.

What patients can do

Patients should be cautious when offered expensive medicines through unofficial channels, especially when the price is dramatically lower than expected.

WHO recommends obtaining medicines from trusted and licensed sources such as authorised pharmacies, hospitals, clinics and healthcare providers. Patients should also examine packaging and check manufacturing and expiry information. If a medicine looks unusual, appears damaged or does not produce an expected therapeutic effect, patients should speak with a doctor or pharmacist promptly.

Importantly, patients should not attempt to determine the authenticity of a cancer medicine based only on its appearance. Counterfeit products can be sophisticated and may require professional verification.

Anyone who suspects that they have received a falsified medicine should contact a healthcare professional and the relevant medicines regulatory authority.

The wider lesson

The Delhi investigation demonstrates how vulnerable patients can become when criminal networks enter the pharmaceutical supply chain.

The alleged use of stolen medicines, counterfeit packaging and fake identification details shows that the threat can arise at multiple points. It also demonstrates why hospitals need strong systems for tracking high-value medicines and investigating discrepancies in stock.

For patients, the most important message is simple: a medicine that appears genuine is not necessarily genuine.

For regulators and healthcare providers, the case reinforces the need for effective supply-chain controls, reliable records and rapid investigation of suspicious products.

And for the pharmaceutical industry, protecting the integrity of medicines is not only a commercial responsibility. It is a public health obligation.

As WHO continues to issue alerts concerning falsified medicines around the world, the Indian crackdown serves as another reminder that counterfeit drugs can exploit the most vulnerable people at the moment they need trustworthy treatment most.

Source and disclaimer: The Independent published on 21 August 2026, together with information from the World Health Organization and other reporting on the Delhi Police investigation. The allegations described above are attributed to police and investigators. The accused are presumed innocent unless proven guilty in court. This article is for general information and does not constitute medical or legal advice.